[go: up one dir, main page]

WO2013162350A3 - Arn antiviral circulaire - Google Patents

Arn antiviral circulaire Download PDF

Info

Publication number
WO2013162350A3
WO2013162350A3 PCT/MY2013/000088 MY2013000088W WO2013162350A3 WO 2013162350 A3 WO2013162350 A3 WO 2013162350A3 MY 2013000088 W MY2013000088 W MY 2013000088W WO 2013162350 A3 WO2013162350 A3 WO 2013162350A3
Authority
WO
WIPO (PCT)
Prior art keywords
tfo
circular
treatment
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MY2013/000088
Other languages
English (en)
Other versions
WO2013162350A2 (fr
Inventor
Abdul Rahman Omar
Bimo A. TEJO
Sheau Wei TAN
Oi Kuan CHOONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiti Putra Malaysia (UPM)
Original Assignee
Universiti Putra Malaysia (UPM)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiti Putra Malaysia (UPM) filed Critical Universiti Putra Malaysia (UPM)
Publication of WO2013162350A2 publication Critical patent/WO2013162350A2/fr
Publication of WO2013162350A3 publication Critical patent/WO2013162350A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des oligonucléotides formant une triple hélice (TFO) destinés à être utilisés dans le traitement de maladies médiées par des virus à ARN monocaténaire, par exemple des coronavirus. L'invention concerne une sélection de séquences de TFO circulaires qui ciblent différentes régions du génome du coronavirus félin virulent et qui bloquent efficacement la réplication du virus. Ainsi, les TFO de la présente invention donnent de nouveaux moyens de traitement des maladies virales. L'invention concerne les nouveaux TFO, des compositions pharmaceutiques les contenant, le nouveau modèle de TFO et leurs utilisations dans le traitement de maladies virales.
PCT/MY2013/000088 2012-04-25 2013-04-23 Arn antiviral circulaire Ceased WO2013162350A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2012001820 2012-04-25
MYPI2012001820 2012-04-25

Publications (2)

Publication Number Publication Date
WO2013162350A2 WO2013162350A2 (fr) 2013-10-31
WO2013162350A3 true WO2013162350A3 (fr) 2013-12-19

Family

ID=49483998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MY2013/000088 Ceased WO2013162350A2 (fr) 2012-04-25 2013-04-23 Arn antiviral circulaire

Country Status (1)

Country Link
WO (1) WO2013162350A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101842679B1 (ko) 2015-10-15 2018-03-28 한국과학기술원 Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제
KR101881502B1 (ko) 2015-10-15 2018-07-25 한국과학기술원 Rna 올리고뉴클레오티드를 포함하는 항바이러스제
WO2017065405A1 (fr) * 2015-10-15 2017-04-20 한국과학기술원 Agent antiviral comprenant un oligonucléotide d'arn
EP3929295A1 (fr) 2020-06-26 2021-12-29 Universitat Pompeu Fabra Arn artificiels pour moduler des fragments d'arn

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148985A1 (en) * 2001-12-05 2003-08-07 David Morrissey Methods and reagents for the inhibition of hepatitis B virus replication

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148985A1 (en) * 2001-12-05 2003-08-07 David Morrissey Methods and reagents for the inhibition of hepatitis B virus replication

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KNAUERT, MELISSA P. ET AL.: "Triplex forming oligonucleotides: sequence- specific tools for gene targeting", HUMAN MOLECULAR GENETICS, vol. 10, no. 20, 2001, pages 2243 - 2251 *
MACRIS, MARGARET A. ET AL.: "Transcription dependence of chromosome gene targeting by triplex-forming oligonucleotides", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3357 - 3362 *
SIMON, PHILIPPE ET AL.: "Targeting DNA with triplex-forming oligonucleotides to modify gene sequence", BIOCHIMIE, vol. 90, no. ISSUE, 2008, pages 1109 - 1116 *
YE, ZHAOYANG ET AL.: "Sequence-specific triple helix formation with genomic DNA", BIOCHEMISTRY, vol. 46, no. 40, 11 September 2007 (2007-09-11), pages 11240 - 11252 *

Also Published As

Publication number Publication date
WO2013162350A2 (fr) 2013-10-31

Similar Documents

Publication Publication Date Title
WO2013074974A3 (fr) Agents arni modifiés
MX2013009191A (es) Oligonucleotidos antisentido.
MX2024005653A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
WO2015042308A3 (fr) Inhibiteurs du vih à base d'arn
WO2013016352A8 (fr) Produits viraux recombinants et procédés pour inhibition de l'expression de dux4
WO2017070626A3 (fr) Vaccins contre les virus respiratoires
WO2015138357A3 (fr) Compositions utiles pour le traitement du déficit en otc
WO2007053696A3 (fr) Inhibition de la replication du virus de la grippe par interference arn
BR112017005111A2 (pt) compostos, composição farmacêutica, usos de um composto ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de um hospedeiro infectado com um papilomavírus humano, usos de um composto, método para a fabricação de um medicamento destinado ao uso terapêutico para o tratamento de uma infecção por papilomavírus
EA201990628A1 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
MY166557A (en) Quinazoline derivatives for the treatment of viral infections and further diseases
EA025278B9 (ru) Антивирусная композиция против заключенных или незаключенных в оболочку днк- или рнк-вирусов
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
WO2016061232A3 (fr) Sharn multiplexés et leurs utilisations
EA202090994A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
WO2012030626A3 (fr) Conception d'analogues d'oligonucléotides utilisables en tant qu'agents thérapeutiques
WO2015168108A3 (fr) Procédés de traitement du cancer au moyen d'un acide nucléique deciblage de mdm2 ou mycn
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
WO2014066915A3 (fr) Procédés et compositions pour produire une activité ss-arni ayant une puissance accrue
RU2015129287A (ru) Апоптоз-индуцирующее средство
WO2019217397A3 (fr) Compositions et méthodes pour améliorer la distorsion de brin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13782115

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 13-02-2015

122 Ep: pct application non-entry in european phase

Ref document number: 13782115

Country of ref document: EP

Kind code of ref document: A2